Drugs / DTaP vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06891872 | May → Dec 2025 overdue | chickenpox, primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP vaccine | “DTaP vaccine” NCT06891872 ↗ |
| Known as | DTaP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06891872 ↗ |
| Modality | Vaccine | “DTaP vaccine” NCT06891872 ↗ |
| Route | Intramuscular | “DTaP: intramuscular injection” NCT06891872 ↗ |